The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards, with Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Castor® branched aortic stent graft and delivery system receiving the China Patent Gold Award. The awarded patent, titled “Branched Covered Stent, Including Its Delivery System and Manufacturing Method” (Patent No.: ZL201310068343.7), is a testament to the company’s innovation in the field of aortic stent technology.
Innovation in Aortic Stent Design and Manufacturing
Castor® branched stent is the world’s first approved branched aortic stent graft designed to treat thoracic aortic dissection involving the arch. The patented technology addresses the design challenges of integrated branched covered stents, achieving a one-piece suture of the stent body and branch, ensuring good support at the connection point. This innovation offers advantages such as low postoperative endoleak rates and high side branch patency rates. The unique “integrated branched covered stent” structure adapts to various arch anatomies, reducing surgical trauma and risks.
Global Recognition and Patent Protection
To date, Castor® branched stent has garnered 26 invention patent authorizations globally, with 18 overseas, covering major medical device markets like Europe and the United States. Previously, a related invention patent for the delivery system, “Branched Covered Stent Delivery System and Its Delivery Method” (Patent No.: ZL200910052079.1), won the 21st China Patent Excellence Award. Castor® branched stent has been recognized with numerous honors, including the National Manufacturing Single Champion Product, Shanghai Science and Technology Progress Award, and Shanghai Brand Certification.
Clinical Impact and Reach
As of November 2024, Castor® branched stent has been introduced to nearly 1,200 hospitals in China and is clinically applied in 22 countries overseas, treating over 28,000 aortic dissection patients worldwide.-Fineline Info & Tech
